ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter

ProQR Therapeutics (NASDAQ: PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA editing program AX-0810, a next-generation follow-on candidate (AX-0811), and the addition of two programs, AX-0422 for Hurler syndrome and AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH). AX-0810: Phase I target engagement